New Zealand company Pathway Therapeutics, a spin off from University of Auckland, has received $12.5 million in funding for its work on PI3K inhibitors
Filed under: kinase | Tagged: Funding, kinase, Pathway Therapeutics, PI3K, Preclinical, Research | Comments Off
Cytopia Limited has announced that they will present details of its FMS kinase program at the Protein Kinase Targets conference which is being held in Boston this month. The company has discovered a series with potent activity that inhibit macrophage function.
Filed under: kinase | Tagged: Cytopia, FMS, kinase, Preclinical, Research | Comments Off
